612
Participants
Start Date
October 11, 2018
Primary Completion Date
April 30, 2024
Study Completion Date
September 30, 2024
IL-1Ra
Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
IL-1Ra Placebo
Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
Derriford Hospital, Plymouth
Royal Hallamshire Hospital, Sheffield
University Hospital of Wales, Cardiff
Leeds General Infirmary, Leeds
Royal Sussex County Hospital, Brighton
Southmead Hospital, Bristol
Addenbrookes Hospital, Cambridge
The Walton Centre, Liverpool
Royal London Hospital, London
St George's Hospital, London
Charing Cross Hospital, London
National Hospital for Neurology and Neurosurgery, Queen Square, London
Northern Care Alliance NHS Foundation Trust, Manchester
Queens Medical Centre, Nottingham
Royal Preston Hospital, Preston
Southampton General Hospital, Southampton
Royal Stoke University Hospital, Stoke-on-Trent
Collaborators (1)
National Institute for Health Research, United Kingdom
OTHER_GOV
Clinical Trials Unit, Manchester
OTHER
Northern Care Alliance NHS Foundation Trust
OTHER
University of Manchester
OTHER